Goldplat CEO Werner Klingenberg discusses dividend policy, share buybacks and the Kilimenpesa sale. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
How to make sense of stock market volatility
How to make sense of stock market volatilityView Video
Goldplat CEO Werner Klingenberg discusses dividend policy, share buybacks and the Kilimenpesa sale
Goldplat CEO Werner Klingenberg discusses dividend policy, share buybacks and the Kilimenpesa saleView Video

Latest Share Chat

Redx Pharma gets milestone sum from AstraZeneca for therapy progress

Thu, 17th Jun 2021 14:07

Redx Pharma PLC - Macclesfield, England-based drug developer focused on cancer and fibrotic disease - Gets milestone payment of USD4 million from AstraZeneca PLC after fibrotic disease therapy makes progress. Says the company has made advances with its RXC006 therapy, a preclinical porcupine inhibitor that targets fibrotic diseases.

The treatment focuses on idiopathic pulmonary fibrosis, a condition in which the lungs become scarred, causing breathing difficulties. According to the British Lung Foundation, in 2012 around 50 people in every 100,000 were diagnosed with idiopathic pulmonary fibrosis.

The company has reached an agreement with AstraZeneca, announced August 4, which includes USD17 million in early payments, to be received before the first clinical trial of the RXC006 porcupine inhibitor therapy. Says once the first trial begins Redx Pharma could receive up to USD360 million in further development and commercial payments tied to certain milestone achievements during the drugs advancement. Redx Pharma is also eligible to receive tiered royalties for potential future net sales of the therapy in the "mid-single digit" percentage range.

Current stock price: 60.45 pence, up 3.3% on Thursday afternoon

Year-to-date change: down 3.3%

By Scarlett Butler; scarlettbutler@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News

UK sends first of 100 million promised vaccine doses to poorer nations

UK sends first of 100 million promised vaccine doses to poorer nations

Today 16:35

Hutchmed research costs deepen loss; expects US launches in 2022, 2023

Hutchmed research costs deepen loss; expects US launches in 2022, 2023

Today 14:51

IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial

IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial

Today 11:33

AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%

AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%

Today 10:58

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.